FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385620764> ?p ?o ?g. }

• W4385620764 endingPage "1457" @default.
• W4385620764 startingPage "1446" @default.
• W4385620764 abstract "Abstract Background Androgen deprivation therapy (ADT) is one of the main treatment modalities for prostate cancer (PCa); however, almost all patients treated with ADT eventually progress into castration‐resistant PCa (CRPC). Although second‐generation androgen receptor (AR) antagonists, such as enzalutamide, have been approved for CRPC treatment, AR signaling in CRPC cells is reactivated through multiple mechanisms, resulting in resistance to treatment and tumor progression with a very poor prognosis. The present study aimed to explore the anticancer effect of a treatment combining AR antagonist enzalutamide with AR degrader IU1 on PCa cells. Methods The joint effects of enzalutamide and IU1 on PCa cell proliferation and apoptosis and associated cell signaling were evaluated in vitro. Mechanistically, the ubiquitination level and half‐life of AR were examined under the combination treatment. The binding of IU1 and enzalutamide to AR was further verified using cellular thermal shift analysis and isothermal dose–response curve fingerprinting. Results The combination of IU1 and three AR antagonists showed synergistic effects in different prostate cell lines. IU1 and enzalutamide synergistically promoted the degradation of AR and AR‐V7 proteins, as well as suppressed the expression levels of AR and AR‐V7 downstream target genes at the transcriptional and protein levels. The combination also synergistically blocked the PCa cell cycle and promoted apoptosis in PCa cell lines. Mechanistically, the combination promoted increased levels of AR ubiquitination. In CRPC cell lines and in the presence of increased androgen concentrations, enzalutamide was still able to bind AR competitively with androgens, reducing the stability of AR and thus promoting the degradation effect of IU1 on AR, synergistically producing an inhibitory effect on PCa cells. Conclusion Taken together, our findings suggest that the combination of AR degrader and enzalutamide potentially represents a new therapeutic strategy for CRPC." @default.
• W4385620764 created "2023-08-08" @default.
• W4385620764 creator A5001329905 @default.
• W4385620764 creator A5009917728 @default.
• W4385620764 creator A5017993003 @default.
• W4385620764 creator A5019319051 @default.
• W4385620764 creator A5020521999 @default.
• W4385620764 creator A5023559188 @default.
• W4385620764 creator A5036660919 @default.
• W4385620764 creator A5045344435 @default.
• W4385620764 creator A5067657792 @default.
• W4385620764 creator A5086782628 @default.
• W4385620764 date "2023-08-07" @default.
• W4385620764 modified "2023-09-24" @default.
• W4385620764 title "IU1 and enzalutamide combination yields synergistic effects on castration‐resistant prostate cancer" @default.
• W4385620764 cites W1993251792 @default.
• W4385620764 cites W1996389184 @default.
• W4385620764 cites W2045589622 @default.
• W4385620764 cites W2092075875 @default.
• W4385620764 cites W2110534364 @default.
• W4385620764 cites W2119504728 @default.
• W4385620764 cites W2141569270 @default.
• W4385620764 cites W2147166694 @default.
• W4385620764 cites W2583517964 @default.
• W4385620764 cites W2622254362 @default.
• W4385620764 cites W2883077013 @default.
• W4385620764 cites W2889540146 @default.
• W4385620764 cites W2894136107 @default.
• W4385620764 cites W2911362138 @default.
• W4385620764 cites W2928567438 @default.
• W4385620764 cites W2937483840 @default.
• W4385620764 cites W3000219741 @default.
• W4385620764 cites W3027456845 @default.
• W4385620764 cites W3094973163 @default.
• W4385620764 cites W3127219762 @default.
• W4385620764 cites W3182894529 @default.
• W4385620764 cites W3197387857 @default.
• W4385620764 cites W3201527831 @default.
• W4385620764 cites W4206070314 @default.
• W4385620764 cites W4307426331 @default.
• W4385620764 cites W4310603203 @default.
• W4385620764 doi "https://doi.org/10.1002/pros.24607" @default.
• W4385620764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37545197" @default.
• W4385620764 hasPublicationYear "2023" @default.
• W4385620764 type Work @default.
• W4385620764 citedByCount "0" @default.
• W4385620764 crossrefType "journal-article" @default.
• W4385620764 hasAuthorship W4385620764A5001329905 @default.
• W4385620764 hasAuthorship W4385620764A5009917728 @default.
• W4385620764 hasAuthorship W4385620764A5017993003 @default.
• W4385620764 hasAuthorship W4385620764A5019319051 @default.
• W4385620764 hasAuthorship W4385620764A5020521999 @default.
• W4385620764 hasAuthorship W4385620764A5023559188 @default.
• W4385620764 hasAuthorship W4385620764A5036660919 @default.
• W4385620764 hasAuthorship W4385620764A5045344435 @default.
• W4385620764 hasAuthorship W4385620764A5067657792 @default.
• W4385620764 hasAuthorship W4385620764A5086782628 @default.
• W4385620764 hasConcept C104317684 @default.
• W4385620764 hasConcept C121608353 @default.
• W4385620764 hasConcept C126322002 @default.
• W4385620764 hasConcept C127561419 @default.
• W4385620764 hasConcept C1491633281 @default.
• W4385620764 hasConcept C185592680 @default.
• W4385620764 hasConcept C190283241 @default.
• W4385620764 hasConcept C2776551883 @default.
• W4385620764 hasConcept C2777899217 @default.
• W4385620764 hasConcept C2780192828 @default.
• W4385620764 hasConcept C502942594 @default.
• W4385620764 hasConcept C55493867 @default.
• W4385620764 hasConcept C61367390 @default.
• W4385620764 hasConcept C62112901 @default.
• W4385620764 hasConcept C71924100 @default.
• W4385620764 hasConcept C98274493 @default.
• W4385620764 hasConceptScore W4385620764C104317684 @default.
• W4385620764 hasConceptScore W4385620764C121608353 @default.
• W4385620764 hasConceptScore W4385620764C126322002 @default.
• W4385620764 hasConceptScore W4385620764C127561419 @default.
• W4385620764 hasConceptScore W4385620764C1491633281 @default.
• W4385620764 hasConceptScore W4385620764C185592680 @default.
• W4385620764 hasConceptScore W4385620764C190283241 @default.
• W4385620764 hasConceptScore W4385620764C2776551883 @default.
• W4385620764 hasConceptScore W4385620764C2777899217 @default.
• W4385620764 hasConceptScore W4385620764C2780192828 @default.
• W4385620764 hasConceptScore W4385620764C502942594 @default.
• W4385620764 hasConceptScore W4385620764C55493867 @default.
• W4385620764 hasConceptScore W4385620764C61367390 @default.
• W4385620764 hasConceptScore W4385620764C62112901 @default.
• W4385620764 hasConceptScore W4385620764C71924100 @default.
• W4385620764 hasConceptScore W4385620764C98274493 @default.
• W4385620764 hasIssue "15" @default.
• W4385620764 hasLocation W43856207641 @default.
• W4385620764 hasLocation W43856207642 @default.
• W4385620764 hasOpenAccess W4385620764 @default.
• W4385620764 hasPrimaryLocation W43856207641 @default.
• W4385620764 hasRelatedWork W2113899328 @default.
• W4385620764 hasRelatedWork W2169404610 @default.
• W4385620764 hasRelatedWork W2469134207 @default.
• W4385620764 hasRelatedWork W2921176969 @default.

• next